BridgeBio Pharma Debt
| BBIO Stock | USD 27.49 1.05 3.97% |
BridgeBio Pharma has over 1.74 Billion in debt which may indicate that it relies heavily on debt financing. At this time, BridgeBio Pharma's Debt Ratio is very stable compared to the past year. With a high degree of financial leverage come high-interest payments, which usually reduce BridgeBio Pharma's Earnings Per Share (EPS).
Asset vs Debt
Equity vs Debt
BridgeBio Pharma's liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. BridgeBio Pharma's cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps BridgeBio Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect BridgeBio Pharma's stakeholders.
For most companies, including BridgeBio Pharma, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for BridgeBio Pharma, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, BridgeBio Pharma's management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Price Book 123.6828 | Book Value (6.51) | Operating Margin (68.50) | Profit Margin (2.02) | Return On Assets (0.49) |
BridgeBio |
BridgeBio Pharma Bond Ratings
BridgeBio Pharma financial ratings play a critical role in determining how much BridgeBio Pharma have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for BridgeBio Pharma's borrowing costs.| Piotroski F Score | 4 | Poor | View |
| Beneish M Score | (3.53) | Unlikely Manipulator | View |
BridgeBio Pharma Debt to Cash Allocation
As BridgeBio Pharma follows its natural business cycle, the capital allocation decisions will not magically go away. BridgeBio Pharma's decision-makers have to determine if most of the cash flows will be poured back into or reinvested in the business, reserved for other projects beyond operational needs, or paid back to stakeholders and investors.
BridgeBio Pharma currently holds 1.74 B in liabilities with Debt to Equity (D/E) ratio of 4.61, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. BridgeBio Pharma has a current ratio of 5.35, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about BridgeBio Pharma's use of debt, we should always consider it together with its cash and equity.BridgeBio Pharma Total Assets Over Time
BridgeBio Pharma Assets Financed by Debt
The debt-to-assets ratio shows the degree to which BridgeBio Pharma uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.BridgeBio Pharma Debt Ratio | 333.0 |
BridgeBio Pharma Corporate Bonds Issued
BridgeBio Net Debt
Net Debt |
|
Understaning BridgeBio Pharma Use of Financial Leverage
Leverage ratios show BridgeBio Pharma's total debt position, including all outstanding obligations. In simple terms, high financial leverage means that the cost of production, along with the day-to-day running of the business, is high. Conversely, lower financial leverage implies lower fixed cost investment in the business, which is generally considered a good sign by investors. The degree of BridgeBio Pharma's financial leverage can be measured in several ways, including ratios such as the debt-to-equity ratio (total debt / total equity), or the debt ratio (total debt / total assets).
| Last Reported | Projected for Next Year | ||
| Net Debt | 1.4 B | 1.4 B | |
| Short and Long Term Debt Total | 1.7 B | 1.1 B | |
| Long Term Debt | 1.7 B | 1.1 B | |
| Long Term Debt Total | 2 B | 2.1 B | |
| Short Term Debt | 8.3 M | 4.8 M | |
| Short and Long Term Debt | 1.3 M | 1.2 M | |
| Net Debt To EBITDA | (2.41) | (2.29) | |
| Debt To Equity | (1.28) | (1.21) | |
| Interest Debt Per Share | 11.13 | 11.69 | |
| Debt To Assets | 3.17 | 3.33 | |
| Long Term Debt To Capitalization | 4.64 | 4.87 | |
| Total Debt To Capitalization | 4.60 | 4.83 | |
| Debt Equity Ratio | (1.28) | (1.21) | |
| Debt Ratio | 3.17 | 3.33 | |
| Cash Flow To Debt Ratio | (0.30) | (0.32) |
Pair Trading with BridgeBio Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if BridgeBio Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BridgeBio Pharma will appreciate offsetting losses from the drop in the long position's value.Moving against BridgeBio Stock
| 0.5 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
| 0.37 | NAMS | NewAmsterdam Pharma | PairCorr |
| 0.34 | OPT | Opthea | PairCorr |
The ability to find closely correlated positions to BridgeBio Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace BridgeBio Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back BridgeBio Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling BridgeBio Pharma to buy it.
The correlation of BridgeBio Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as BridgeBio Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if BridgeBio Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for BridgeBio Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of BridgeBio Pharma Fundamentals Over Time. To learn how to invest in BridgeBio Stock, please use our How to Invest in BridgeBio Pharma guide.You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BridgeBio Pharma. If investors know BridgeBio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BridgeBio Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.42) | Revenue Per Share 1.194 | Quarterly Revenue Growth (0.33) | Return On Assets (0.49) | Return On Equity (17.90) |
The market value of BridgeBio Pharma is measured differently than its book value, which is the value of BridgeBio that is recorded on the company's balance sheet. Investors also form their own opinion of BridgeBio Pharma's value that differs from its market value or its book value, called intrinsic value, which is BridgeBio Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BridgeBio Pharma's market value can be influenced by many factors that don't directly affect BridgeBio Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BridgeBio Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if BridgeBio Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BridgeBio Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
What is Financial Leverage?
Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.Leverage and Capital Costs
The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.Benefits of Financial Leverage
Leverage provides the following benefits for companies:- Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
- It provides a variety of financing sources by which the firm can achieve its target earnings.
- Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.